The Evolving Biosimilar Tendering Landscape
Biologics are among the biggest drivers of pharmaceutical spending growth in the U.S. By 2020 patents for 9 of the top 20 best-selling biologics will expire. As a result, the U.S. market is preparing to embrace biosimilars as lower cost alternatives to their branded counterparts—a way to contain spending while improving access to patients.
What can U.S. pharma companies glean from experiences in the European market, where biosimilar use is more prevalent?
We tackled this discussion at Rainmaker19 in March. Download the full presentation to discover:
- The essential considerations of contracting and pricing for biosimilars, including both tendering and contracting processes
- Different approaches to pricing, contracting and looking at gross-to-net in the biosimilar pricing environment
- How to use pricing and contracting strategies to build a competitive advantage with biosimilars
- Where technology fits and helps you understand your market
Learn what you should be thinking about today to prepare for biosimilars. Download the presentation today.